Prognostic Implications of Metabolic Syndrome Phenotype in Patients with COPD: A 3-year Follow-up Study of KOLD Cohort
분야
의약학 > 내과학
저자
임성용 , 오연목 , 서준범 , 유광하 , 이지현 , 김은경 , 김태형 , 김우진 , 이진화 , 이상민 , 이상엽 , 신태림 , 윤호일 , 이진국 , 신승수 , 박용범 , 이재승 , 이세원 , 허진원 , 이상도 , ( Kold Study Investigators )
발행기관
대한결핵 및 호흡기학회
간행물정보
대한결핵및호흡기학회 추계학술발표초록집 2012년, 제114권 203(총1페이지)
파일형식
0y909913.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    1,000원
    적립금
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    Objectives: Metabolic syndrome (MetS) refers to a cluster of abdominal obesity, dyslipidemia, hypertension, insulin resistance that predisposes to cardiovascular disease. MetS affects more than 30% of adults in Korea and coexisting with COPD is frequent. Previous cross-sectional studies have suggested associations of impaired lung function with MetS. In contrast, several studies reported reduced all-cause mortality in obese COPD. The aim of this study was to explore whether MetS phenotype has different prognostic implications in COPD patients, particularly focusing on the rate of decline in FEV1 and SGRQ. Methods: A total of 189 eligible patients with COPD were selected from the Korean Obstructive Lung Disease (KOLD) cohort. The presence of MetS was defined according to the AHA/NHLBI criteria. The rate of annual decline in FEV₁and SGRQ were assessed between MetS (+) and MetS (-) group. The presence and number of exacerbation and mortality were also compared. Results: The prevalence of MetS was 32.3%. Patients with MetS (+) had lower FEV1 decline and lower SGRQ decline over 3-year follow-up. In multivariate analyses, MetS remained significant predictor of FEV1 and SGRQ decline independently of confounding factors (P=0.024, P=0.026, respectively). Number of exacerbation requiring hospitalization and mortality were significantly lower in MetS (+) group (P=0.037, P=0.012, respectively). Conclusions: MetS phenotype may relate to reduced deterioration of lung function and quality of life, and reduced exacerbation and mortality in Korean COPD.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.